Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes

Table 1 Clinical characteristics of patients with type 2 diabetes who received omarigliptin divided according to add-on to or switched from daily dipeptidyl peptidase-4 inhibitor

	AO (n = 18)	L→Om (n = 6)	S→Om (n = 10)	V→Om (n = 15)
Male : Female	13 : 5	4 : 2	5 : 5	13 : 2
Age (yr)	66.8 ± 12.1	75.2 ± 9.0	63.6 ± 15.7	70.1 ± 8.7
Duration (yr)	12.0 ± 10.1	15.5 ± 10.7	11.2 ± 5.6	12.9 ± 4.8
BMI (kg/m2)	24.1 ± 3.3	24.9 ± 1.6	23.5 ± 2.4	23.7 ± 3.4
eGFR (mL/min/1.73 m2)	63.6 ± 19.5	45.0 ± 22.2a	76.1 ± 17.5	63.3 ± 15.7
HbA1c (%)	7.48 ± 1.28	6.33 ± 0.79	6.88 ± 0.37	7.14 ± 0.66
Metformin use	8 (44%)	1 (17%)	4 (40%)	6 (40%)
Insulin secretagogues1 use	5 (28%)	0 (0%)	4 (40%)	8 (53%)
Insulin use	2 (11%)	0 (0%)	1 (10%)	3 (20%)

¹Insulin secretagogues include sulfonylurea and glinide, but not dipeptidyl peptidase-4 inhibitor.

Data are shown as mean ± SD or n (%) unless otherwise indicated. AO: Add-on; BMI: Body mass index; eGFR: Estimated glomerular filtration rate; HbA1c: Hemoglobin A1c; L→Om: Switch from linagliptin to omarigliptin; S→Om: Switch from sitagliptin to omarigliptin; V→Om: Switch from vildagliptin to omarigliptin. ^aP < 0.05 vs S→Om group (multiple comparison).

Table 2 Clinical characteristics of patients with type 2 diabetes between the improved/stable and worsened glycemic control after switching from vildagliptin to omarigliptin

	Improved/stable (n = 5)	Worsened (n = 10)	P value
Male : Female	4 : 1	9 : 1	NS
Age (yr)	67.8 ± 10.2	71.2 ± 8.1	NS
Duration (yr)	9.8 ± 4.1	14.5 ± 4.5	NS
BMI (kg/m2)	25.1 ± 4.3	23.0 ± 2.8	NS
eGFR (mL/min/1.73 m2)	71.2 ± 19.2	59.4 ± 12.9	NS
HbA1c (%)	7.48 ± 0.97	6.97 ± 0.41	NS
Metformin use	2 (40%)	4 (40%)	NS
Insulin secretagogues1 use	3 (60%)	5 (50%)	NS
Insulin use	2 (40%)	1 (10%)	NS

¹Insulin secretagogues include sulfonylurea and glinide but not dipeptidyl peptidase-4 inhibitor.

Data are shown as mean ± SD or n (%) unless otherwise indicated. BMI: Body mass index; eGFR: Estimated glomerular filtration rate; HbA1c: Hemoglobin A1c; NS: Not significant.

Table 3 Multivariate logistic regression analysis on worsening of glycemic control after omarigliptin administration

	Odds ratio	95%CI	P value
Sex (male)	0.837	0.03-24.30	NS
Age	1.004	0.82-1.23	NS
Insulin secretagogues1 use	0.575	0.04-7.72	NS
Insulin use	0.038	0.001-1.460	NS
BMI at omarigliptin administration	0.757	0.45-1.26	NS
eGFR at omarigliptin administration	0.941	0.84-1.06	NS
HbA1c at omarigliptin administration	5.862	0.86-39.80	NS
Switching from vildagliptin	146.62	7.00-3072.60	0.0013

¹Insulin secretagogues include sulfonylurea and glinide, but not dipeptidyl peptidase-4 inhibitor.

BMI: Body mass index; eGFR: Estimated glomerular filtration rate; HbA1c: Hemoglobin A1c; NS: Not significant; CI: Confidence interval.